RxDoctor Payments Data

Mary Borses, MD

Cardiovascular Disease · Monterey, CANPI 1164513297

Payments from drug & device makers

$6,078in general payments, 2019–2025

Across 200 payments — averaging $30.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • Novartis$610
  • Amgen$517
  • Pfizer$370
  • Abbott$331
  • Esperion Therapeutics, Inc.$273
  • plus $2K from 25 others

What the payments were for

  • Travel & lodging$70412%
  • Food & beverage$5,24386%
  • Education$401%
  • Other$901%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,078 in reported general payments places this provider in the 65th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$462,682
Medicare patients
1,054
Services billed
4,535

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban243$350,569
JardianceEmpagliflozin84$118,306
XareltoRivaroxaban67$105,797
EntrestoSacubitril/Valsartan43$71,255
Repatha SureclickEvolocumab46$66,692
Atorvastatin Calcium570$6,440
Metoprolol Succinate265$4,305
Rosuvastatin Calcium145$2,776
Ezetimibe83$2,707
Digoxin83$2,365
Flecainide Acetate52$2,276
Losartan Potassium190$2,197
Carvedilol161$2,059
Spironolactone113$1,790
Potassium Chloride62$1,732

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$370$350,569243 claims
Boehringer IngelheimJardiance$186$118,30684 claims
Johnson & JohnsonXarelto$124$105,79767 claims
NovartisEntresto$610$71,25543 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Monterey

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →